PP-092 Novel role of peripheral blood mononuclear cells in HBV intrauterine infection
International Journal of Infectious Diseases
Objective: Observation of chronic hepatitis B and asymptomatic carriers to obtain HBV-DNA negative efficacy and non-specific immune response relationship. Methods: 255 cases of patients will be divided into 4 group; observation lamivudine and Mycobacterium FU36 with Chinese medicine group (A) and lamivudine with the Chinese group (B), HBV-DNA on the efficacy, safety and efficacy issues, 3 month course of treatment, follow-up 9 months. Results: 1) B group of chronic hepatitis B have HBV-DNA,
... B have HBV-DNA, respectively, 30.30% and 26.47% of the significant efficiency, it was significantly higher than non-carriers of asymptomatic has a case to obtain the effect markedly, P<0,01; 2) A group of chronic hepatitis B in HBV-DNA were 82.75% and 76.66% of the significant efficiency, was significantly higher than group B, only 30.30% and 26.47% efficiency of the significant, P <0,01; 3) A group of HBeAg negative carriers of asymptomatic HBV-DNA has the remarkable efficiency of 80.64%, significantly higher than the B group is not an case,A group of HBeAg-positive carriers of asymptomatic HBV-DNA, only 5.71% of the significant efficiency, P<0,01, etc. Course of treatment there is no adverse reaction. Conclusions: Non-specific immune status changes, and abnormal alanine aminotransferase, and HBV-DNA was markedly effect the results significantly correlated, induced HBeAg-specific immune tolerance of HBV-DNA to obtain the effect of markedly present only for the "impact" role.